Niagen Bioscience, Inc.
NAGE
$6.76
$0.223.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 8.55M | 1.49M | -1.35M | -3.53M | -4.94M |
| Total Depreciation and Amortization | 1.48M | 1.50M | 1.58M | 1.66M | 1.71M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.06M | 4.08M | 4.66M | 5.22M | 5.79M |
| Change in Net Operating Assets | 3.13M | -2.89M | -3.81M | 1.28M | 4.56M |
| Cash from Operations | 12.11M | 4.18M | 1.08M | 4.62M | 7.12M |
| Capital Expenditure | -163.00K | -115.00K | -100.00K | -98.00K | -148.00K |
| Sale of Property, Plant, and Equipment | 20.00K | 20.00K | 0.00 | 5.00K | 5.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -143.00K | -95.00K | -100.00K | -93.00K | -143.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.00K | -10.00K | -9.00K | -17.00K | -15.00K |
| Issuance of Common Stock | 5.43M | 1.64M | 598.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -52.00K | -86.00K | -86.00K | -86.00K | -75.00K |
| Cash from Financing | 5.37M | 1.55M | 503.00K | -103.00K | -90.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.34M | 5.63M | 1.48M | 4.42M | 6.88M |